| CEA (Carcinoembryonic Antigen) |
Diagnostic and Prognostic |
CEA is a blood marker used in screening and monitoring colorectal
cancer. Elevated CEA levels may indicate the presence of the disease,
and it can be used to assess treatment response and disease recurrence. |
(101) |
| KRAS Mutation |
Predictive and Prognostic |
KRAS mutation status is important for predicting response to
anti-EGFR targeted therapies. Mutations in KRAS are associated with
resistance to these treatments, impacting treatment choices and prognosis. |
(25) |
| BRAF Mutation |
Prognostic |
BRAF
V600E mutations are associated with poor prognosis in
colorectal cancer. Identifying this mutation helps in stratifying
patients for more aggressive treatment strategies. |
(24) |
| Microsatellite Instability (MSI) |
Diagnostic and Prognostic |
MSI status helps in identifying a subset of colorectal cancer
patients with a better prognosis and predicting their response to
immunotherapies. It is also used in diagnosing Lynch syndrome. |
(102) |
| TP53 Mutation |
Prognostic |
TP53 mutations are associated with more aggressive tumor behavior
and poor prognosis in colorectal cancer. Understanding TP53 status
helps guide treatment planning. |
(22) |
| EGFR Expression |
Predictive and Prognostic |
Assessing EGFR expression can help in predicting response to
anti-EGFR targeted therapies. Higher EGFR expression may indicate
a better response to these treatments. |
(103) |
| Mismatch Repair (MMR) Proteins |
Diagnostic and Prognostic |
Abnormal expression of MMR proteins is associated with MSI
and can help diagnose Lynch syndrome. It is also used to determine
MSI status and guide therapy choices. |
(104) |
